Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc.（INBX）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · INBX · 截至 2026年6月9日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
3
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Inhibrx Biosciences, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
INBX 季度内部人买卖趋势
INBX 内幕交易卖出 · INBX 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · INBX CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
INBX 高管卖出股份 · INBX 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Oct 7, 2025 | VIKING GLOBAL INVESTORS LP 10 percent owner | Sale | 308,643 | $9.95M⚡ | Form 4 |
| Oct 7, 2025 | VIKING GLOBAL INVESTORS LP 10 percent owner | Sale | 25,042 | $808K | Form 4 |
| Oct 7, 2025 | VIKING GLOBAL INVESTORS LP 10 percent owner | Sale | 16,315 | $526K | Form 4 |
| Mar 27, 2025 | Kayyem Jon Faiz Director | Gift | 90,000 | — | Form 4 |
| Dec 16, 2024 | Kayyem Jon Faiz Director | Gift | 500,000 | — | Form 4 |
| Dec 16, 2024 | Kayyem Jon Faiz Director | Gift | 250,000 | — | Form 4 |
| Dec 6, 2024 | Kayyem Jon Faiz Director | Gift | 52,000 | — | Form 4 |
| Nov 20, 2024 | Kayyem Jon Faiz Director | Purchase | 18,750 | $266K | Form 4 |
| Nov 19, 2024 | Kayyem Jon Faiz Director | Purchase | 34,843 | $496K | Form 4 |
| Oct 3, 2024 | Vuori Kristiina MD Director | Purchase | 6,667 | $100K | Form 4 |
| Sep 16, 2024 | Lappe Mark CEO · Director | Purchase | 13,037 | $223K | Form 4 |
| Sep 12, 2024 | Lappe Mark CEO · Director | Purchase | 26,963 | $406K | Form 4 |
| Sep 11, 2024 | Vuori Kristiina MD Director | Purchase | 6,457 | $97K | Form 4 |
| Sep 10, 2024 | Vuori Kristiina MD Director | Purchase | 179 | $3K | Form 4 |
| Sep 10, 2024 | Lappe Mark CEO · Director | Purchase | 8,500 | $129K | Form 4 |
| Sep 9, 2024 | Lappe Mark CEO · Director | Purchase | 9,500 | $144K | Form 4 |
| Sep 6, 2024 | Lappe Mark CEO · Director | Purchase | 26,000 | $398K | Form 4 |
| May 30, 2024 | VIKING GLOBAL INVESTORS LP 10 percent owner | Other | 511,627 | $15.35M⚡ | Form 4 |
| May 30, 2024 | Lappe Mark CEO · Director | Other | 59,462 | $1.78M⚡ | Form 4 |
| May 30, 2024 | Kayyem Jon Faiz Director | Other | 25,000 | $750K | Form 4 |
| May 30, 2024 | FORSYTH DOUGLAS Director | Other | 598,257 | $17.95M⚡ | Form 4 |
| May 28, 2024 | Eckelman Brendan P. Chief Scientific Officer | Sale | 300,000 | $10.29M⚡ | Form 4 |
| May 30, 2024 | Eckelman Brendan P. Chief Scientific Officer | Other | 160,000 | $4.80M⚡ | Form 4 |
| Aug 28, 2023 | VIKING GLOBAL INVESTORS LP 10 percent owner | Purchase | 511,627 | $9.90M⚡ | Form 4 |
| Mar 1, 2023 | Eckelman Brendan P. Chief Scientific Officer | Sale | 39,600 | $958K | Form 4 |
VIKING GLOBAL INVESTORS LP
10 percent owner
日期
Oct 7
股数
308,643
均价
$32.25
总金额
$9.95M ⚡
VIKING GLOBAL INVESTORS LP
10 percent owner
日期
May 30
股数
511,627
均价
$30.00
总金额
$15.35M ⚡
Eckelman Brendan P.
Chief Scientific Officer
日期
May 28
股数
300,000
均价
$34.30
总金额
$10.29M ⚡
Eckelman Brendan P.
Chief Scientific Officer
日期
May 30
股数
160,000
均价
$30.00
总金额
$4.80M ⚡
VIKING GLOBAL INVESTORS LP
10 percent owner
日期
Aug 28
股数
511,627
均价
$19.35
总金额
$9.90M ⚡
Eckelman Brendan P.
Chief Scientific Officer
日期
Mar 1
股数
39,600
均价
$24.20
总金额
$958K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 INBX 内幕交易
INBX 内幕交易
Inhibrx Biosciences, Inc.（INBX）内幕交易数据来源于公司内部人（包括VIKING GLOBAL INVESTORS LP (10 percent owner)）提交的SEC Form 4申报文件。过去12个月内，1位内部人向SEC提交了交易申报。INBX内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Inhibrx Biosciences, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
INBX 内幕交易 · 5个问题Inhibrx Biosciences, Inc.（INBX）的内部人包括高管和董事，如VIKING GLOBAL INVESTORS LP (10 percent owner)等。过去12个月内，1位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026